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Abstract
Background: Cutaneous injection-related infections (CIRI), such as abscesses and cellulitis, are
common and preventable among injection drug users (IDU). However, risk factors for CIRI have
not been well described in the literature. We sought to characterize the risk factors for current
CIRI among individuals who use North America's first supervised injection facility (SIF).
Methods: A longitudinal analysis of factors associated with developing a CIRI among participants
enrolled in the Scientific Evaluation of Supervised Injecting (SEOSI) cohort between January 1, 2004
and December 31, 2005 was conducted using generalized linear mixed-effects modelling.
Results: In total, 1065 participants were eligible for this study. The proportion of participants with
a CIRI remained under 10% during the study period. In a multivariate generalized linear mixed-
effects model, female sex (Adjusted Odds Ratio (AOR) = 1.68 [95% Confidence Interval (CI): 1.16–
2.43]), unstable housing (AOR = 1.49 [95% CI: 1.10–2.03]), borrowing a used syringe (AOR = 1.60
[95% CI: 1.03–2.48]), requiring help injecting (AOR = 1.42 [95% CI: 1.03–1.94]), and injecting
cocaine daily (AOR = 1.41 [95% CI: 1.02–1.95]) were associated with an increased risk of having a
CIRI.
Conclusion: CIRI were common among a subset of IDU in this study, including females, those
injecting cocaine daily, living in unstable housing, requiring help injecting or borrowing syringes. In
order to reduce the burden of morbidity associated with CIRI, targeted interventions that address
a range of factors, including social and environmental conditions, are needed.
Background
Injection drug use remains a major public health concern
worldwide. While researchers and policy makers have
focused much attention on the transmission of blood-
borne viruses (e.g., human immunodeficiency virus
[HIV], hepatitis C virus [HCV]) among injection drug
users (IDU) [1-3], considerably less attention has been
devoted to the problem of bacterial infections of the skin
[4]. A recent report by the United States Centres for Dis-
ease Control and Prevention highlighted the dearth of
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research on cutaneous injection-related infections (CIRI)
among IDU and cited reports of recent and dramatic
increases in CIRI, including abscesses and cellulitis,
among IDU in England [5]. In addition, CIRI are the pri-
mary reason that IDU seek treatment at an emergency
department in some settings [6].
The prevalence of CIRI among IDU typically ranges from
10% to 30% [7,8]. The variability in prevalence estimates
may be due to differences in measurement of the occur-
rence of CIRI (e.g., reporting current vs. ever having a
CIRI), the definition of CIRI (e.g., injection-related vs. any
drug-related) and the fact that there are currently no
standard guidelines with regard to reporting of CIRI based
on severity [4]. Other factors may be the exploration of
different risk factors for developing CIRI across settings,
for example differences in types of drugs used (e.g., black
tar heroin in California, United States vs. white heroin in
British Columbia, Canada), intensity of drug use, and
availability and access to clean injection paraphernalia
[9].
However, certain factors have been shown to be consist-
ently associated with developing a CIRI in particular cit-
ies. For example: injecting under the skin (also known as
"skin popping") in San Francisco and Glasgow [8,10,11];
frequent injection in Amsterdam and Vancouver [12,13];
and injection of heroin plus cocaine (i.e. "speedballs") in
San Francisco and Amsterdam [8,13] have been associated
with CIRI. However, most of these analyses were based on
cross-sectional investigations few prospective studies
exist. We conducted the present longitudinal study to
characterize risk factors of developing a CIRI among IDU.
Methods
Data source: Scientific Evaluation of Supervised Injection
In September 2003, a comprehensive evaluation of Insite,
North America's first supervised injection facility (SIF),
was initiated. Users of the SIF, located in Vancouver's
Downtown Eastside (DTES) neighbourhood, were ran-
domly invited to enroll in a prospective cohort study
known as the Scientific Evaluation of Supervised Injection
(SEOSI) and have since been interviewed semi-annually
[14]. The methodological details have been described
elsewhere [15]. Briefly, to be recruited into the SEOSI
cohort, individuals had to have performed at least two
injections at the SIF, been at least 19 years old and pro-
vided informed consent. Furthermore, the questionnaire
is interviewer-administered and elicits a range of informa-
tion, including information specific to socio-demo-
graphic characteristics, risk behaviours, and involvement
in addiction treatment. This is followed by blood testing
for HIV and HCV for those who previously tested negative
and a nurse-administered questionnaire on health status.
A database in the SIF tracks key events, including utiliza-
tion and the types of drug being injected. The SEOSI
cohort has received approval from the Providence Health
Care/University of British Columbia Ethics Board.
To be eligible for this study, participants must have com-
pleted both the interviewer-administered and nurse-
administered baseline questionnaires during the study
period (January 1, 2004 to December 31, 2005.)
Outcome Measure and Explanatory Variables
The primary outcome for this analysis (dependent varia-
ble) was a current CIRI reported to and visually confirmed
(e.g., pain, redness, induration, and fluctuation) by the
study nurse in response to the question "Do you presently
have any sores or abscesses from where you have been
injecting?". Explanatory variables examined in this analy-
sis included: age (per year older); sex (female vs. male);
unstable housing, defined as living in a single room occu-
pancy hotel, shelter, recovery or transition house, jail, on
the street, or having no fixed address as opposed to living
in an apartment or house (yes vs. no); residence in the
DTES (yes vs. no); sex trade involvement (yes vs. no); bor-
rowing used syringes (yes vs. no); requiring help injecting
(yes vs. no); using puddle water for injecting (yes vs. no);
injecting cocaine daily (yes vs. no); injecting heroin daily
(yes vs. no), injecting crack cocaine daily (yes vs. no);
injecting crystal methamphetamine daily (yes vs. no);
injecting "speedballs" daily (yes vs. no); the proportion of
all injections at SIF (always vs. < always); HIV serostatus
(positive vs. negative); and HCV serostatus (positive vs.
negative). Variable definitions were consistent with previ-
ous work [16-19]. All variables referred to the six months
prior to the interview, except for unstable housing and res-
idence in the DTES, which referred to resident status at the
more recent interview.
Statistical Analysis
The proportion of SEOSI participants who reported hav-
ing a CIRI was inspected graphically over time. Univariate
and multivariate statistics, including generalized linear
mixed-effects modeling, were used to examine factors
associated with having a CIRI over time. Generalized lin-
ear mixed-effects modeling is a longitudinal technique
that analyzes individual trajectories and produces corre-
lates. This analytic technique was chosen because of its
flexibility in variable parameters (e.g., fixed, time-
updated, random), its ability to capture heterogeneity of
subjects and within-subject correlation, and its attempt to
identify individual-level factors [20]. Independent varia-
bles were either fixed (e.g., sex) or time-updated (e.g., age,
all behavioural variables considered, HIV and HCV
serostatus) in this model. Random variation between
individuals was accounted for by using random inter-
cepts. Variables significant at the univariate level (p  <
0.05) were included in the multivariate model. The dataBMC Public Health 2008, 8:405 http://www.biomedcentral.com/1471-2458/8/405
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were analyzed using SAS version 9.1 (SAS Institute, Cary,
NC, USA.) All reported p-values were two-tailed.
Results
Of the 1090 participants recruited into the SEOSI cohort
since November 2003, 1065 (97%) completed both a
baseline interviewer-administered questionnaire and a
nurse-administered questionnaire after recruitment into
SEOSI cohort. Among these participants, 877 (82%)
returned for at least one follow-up visit, and 312 (29%)
were female. The median age was marginally younger for
those who reported a CIRI at baseline when compared
with those who did not at baseline (36 [IQR: 31–43] vs.
39 [IQR: 33–45], p = 0.095). As shown in Figure 1, the
proportion of participants reporting a current CIRI in this
study was fairly consistent over the two year study period,
ranging from 6% to 10%, although the proportion
declined slightly between the baseline and first follow-up
visit. At baseline, 106 (10%) of participants reported a
CIRI. There were 14 (1%) individuals with missing data
on HIV serostatus and 33 (3%) individuals with missing
data on HCV serostatus at baseline; due to these small
counts, these individuals were excluded from further anal-
yses.
Using longitudinal methods, factors associated with
reporting a current CIRI at the univariate and multivariate
level are presented in Table 1. In univariate analyses,
being older and reporting use of the SIF for all injections
was associated with a decreased likelihood of developing
a current CIRI. Female sex, living in unstable housing,
involvement in the sex trade, borrowing a used syringe,
requiring help injecting, injecting cocaine daily, injecting
heroin daily, and injecting "speedballs" daily were posi-
tively associated with reporting a current CIRI.
As displayed in the multivariate model in Table 1, partici-
pants who reported a current CIRI were more likely to be
female (Adjusted OR (AOR) = 1.68 [95% Confidence
Intervals {CI}: 1.16–2.43]); live in unstable housing
(AOR = 1.49 [95% CI: 1.10–2.03]); borrow used syringes
(AOR = 1.60 [95% CI: 1.03–2.48]); require help injecting
(AOR = 1.42 [95% CI: 1.03–1.94]); and inject cocaine
daily (AOR = 1.41 [95% CI: 1.02–1.95]).
Discussion
In this study we found that the proportion of IDU report-
ing a CIRI remained within the range of six to 10 per cent
over a median follow-up of 12.6 (IQR: 6.2–17.7) months
after SIF recruitment. The level of CIRI is relatively low in
the context of previously reported prevalence (10–30%
[7,8]). However, considering that it is based on reporting
a current infection, the level in this study is concerning.
Furthermore, our results indicate that being female, living
in unstable housing, borrowing syringes, requiring help
Proportion of SEOSI participants reporting a CIRI (January 1,  2004 – December 31, 2005, n = 1065) Figure 1
Proportion of SEOSI participants reporting a CIRI 
(January 1, 2004 – December 31, 2005, n = 1065).
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Table 1: Univariate and multivariate analysis of developing a 
CIRI among SEOSI participants (n = 1065)
Variable OR (95% - CI) AOR (95% - CI)
Age
(per year older) 0.98 (0.96 – 1.00) 1.00 (0.98 – 1.02)
Sex
(Female vs. Male) 1.90 (1.39 – 2.58) 1.68 (1.16 – 2.43)
Unstable housing
(Yes vs. No) 1.56 (1.15 – 2.12) 1.49 (1.10 – 2.03)
DTES residence
(Yes vs. No) 1.33 (0.96 – 1.85)
Sex trade*
(Yes vs. No) 1.74 (1.24 – 2.45) 1.02 (0.67 – 1.56)
Borrowing syringes*
(Yes vs. No) 1.88 (1.22 – 2.88) 1.60 (1.03 – 2.48)
Requiring help inject*
(Yes vs. No) 1.85 (1.37 – 2.50) 1.42 (1.03 – 1.94)
Use puddle to inject*
(Yes vs. No) 1.32 (0.83 – 2.11)
Cocaine injection*
(Daily vs. Not) 1.66 (1.23 – 2.25) 1.41 (1.02 – 1.95)
Heroin injection*
(Daily vs. Not) 1.53 (1.14 – 2.04) 1.26 (0.93 – 1.72)
Crack injection*
(Daily vs. Not) 1.54 (0.96 – 2.46)
Crystal meth. injection*
(Daily vs. Not) 1.48 (0.73 – 3.02)
Speedball injection*
(Daily vs. Not) 2.00 (1.35 – 2.96) 1.37 (0.89 – 2.11)
SIF use
(Always vs. Not) 0.47 (0.23 – 0.94) 0.58 (0.29 – 1.19)
HIV serostatus
(Yes vs. No) 1.23 (0.85–1.77)
HCV serostatus
(Yes vs. No) 1.35 (0.81 – 2.25)
Note: *activity past 6 months, DTES = downtown eastside, meth. = 
methamphetamine, SIF = supervised injection facilityBMC Public Health 2008, 8:405 http://www.biomedcentral.com/1471-2458/8/405
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injecting, and injecting cocaine daily were independently
associated with developing a CIRI.
The observed associations between female sex, daily
cocaine injection, living in unstable housing and an ele-
vated risk of having a CIRI are congruent with previous
analyses. The link between being female and having a
CIRI echoes the findings of previous studies [10,12,13],
and may reflect, in part, the complex gender dynamics
that exist within injection drug using populations where
women are often dependent on men for the attainment
and administration of drugs [21].
With regard to the association between cocaine injection
and development of CIRI [12,13], cocaine's anaesthetic
properties may make it more difficult for individuals to
know whether or not they are hitting a vein (as opposed
to injecting in the surrounding tissue or skin), resulting in
trauma through repetitive attempts to access the vein
[22,23]. Missing a vein increases vulnerability for CIRI
since injecting into the surrounding tissue creates a niche
environment in which bacteria can thrive [9]. Further, due
to cocaine's short half-life in comparison to heroin, it is
often injected many more times than heroin, which also
increases the likelihood of CIRI and transmission of
blood-borne viruses such as HIV [16]. Indeed, as indi-
cated by our findings and others, intensity of drug use
appears to play a role in CIRI development, as individuals
who inject at least once daily have been repeatedly identi-
fied to be at elevated risk for developing a CIRI [12,13].
The association between homelessness and an injection
site infection has been reported [24]. According to the
'risk environment' framework, as proposed by Rhodes et
al., structural and environmental factors are important to
consider when assessing risks for drug-related harms as
they shape the context in which individual behaviour
occurs [24]. It may be that those in our study who
reported living in unstable housing may also frequent
risky injecting environments, which in turn lead to rushed
injections (i.e., not taking time to go through every step of
the injection process to ensure a safer injection) or inject-
ing in a high-risk location like the groin for a 'quick fix'
[25]. A recent review of homelessness found that between
15–50% of homeless individuals inject drugs, and it was
further reported that breaks of the skin were common
among such individuals, often leading to bacterial infec-
tions due to a lack of hygiene [26]. In addition, the small
size, shared facilities and often unhygienic environment
of single room occupancy hotels that are common in the
DTES promote disease transmission [27].
Among the novel findings in the present study are the
associations between CIRI development and borrowing
syringes and requiring help injecting. Borrowing used
syringes is known to be a strong risk factor for blood-
borne viral transmission [28,29]. Our study shows that
the transmission of CIRI-related bacteria via sharing of
syringes should also be considered by IDU, health profes-
sionals, and public health practitioners. However, it is
also possible that sharing syringes is not the active vector
in this transmission and that this transmission is by other
injection drug paraphernalia. Requiring help injecting, a
risk factor for CIRI in this study, may increase risk of expo-
sure to bacteria when the individual who is administering
the injection injects themselves before injecting the per-
son who requires assistance (i.e., "second on the needle").
This study has several limitations. Firstly, we were unable
to examine "skin popping" as an independent variable in
this study due to a low number of participants reporting
this behaviour. This may be due to the fact that the prac-
tice is more commonly associated with injection of "black
tar" heroin, a type rarely used in Vancouver. Given that
our "skin popping" question in the study questionnaire
pertained to intentional "skin popping" it is also possible
that participants who injected subcutaneously or intra-
muscularly by mistake were not captured. Secondly, our
study relies on self-report and therefore is potentially vul-
nerable to social desirability bias. However, we know of
no reason to suspect differential reporting between partic-
ipants with or without CIRI. Thirdly, it is possible that
individuals who inject at the SIF are different from those
who do not. A study by Wood et al. found that IDU that
used the SIF were more likely to be at a higher risk of
blood-borne disease infection and overdose compared
with IDU who did not use the SIF [30]. Therefore, our
results may not be generalizable to the broader local IDU
population. However, the SEOSI cohort was randomly
recruited from within the SIF [15]. Therefore, we believe
that our sample is representative of SIF users. Fourthly, the
external validity of this study should be interpreted with
caution, as Vancouver's DTES neighbourhood is unique
due to its large open drug scene and the high prevalence
of cocaine injection. Finally, this study investigates only
CIRI related to injection drug use and not other behav-
iours for example. However, we feel this is an important
distinction as it serves to reduce misclassification bias
based on reporting CIRI that may be related to other fac-
tors such as picking the skin induced by cocaine psychosis
[16].
The prevalence of CIRI among IDU in this study suggests
that a higher priority should be placed on reducing the
incidence of these preventable infections. Since a positive
impact of the SIF on access to assessment, care, and treat-
ment of CIRI has been noted [31], it is likely that the rate
of CIRI observed here may be lower than the rate observed
in the broader community. Combining harm reduction
(e.g., needle exchange programs and supervised injectionBMC Public Health 2008, 8:405 http://www.biomedcentral.com/1471-2458/8/405
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facilities) and treatment services may be of value to pre-
vent and/or reduce the risk for CIRI development. Specif-
ically, integrating wound management care into existing
harm reduction services, such as needle exchange pro-
grams and SIF, in community settings has been found to
be feasible, cost-effective and beneficial for preventing
and treating CIRI and other related skin infections such as
necrotizing fasciitis [32]. Expansion of such programs
among harm reduction services may be reasonable, espe-
cially as many IDU remain medically underserved [33].
Conclusion
In summary, we found that over a two-year period that
between six and 10 percent of IDU presented with a CIRI.
Risk factors for CIRI development included being female,
living in unstable housing, borrowing used syringes,
requiring help injecting and injecting cocaine daily. These
findings collectively point to the need to develop a range
of interventions that target the various individual, social
and environmental risks for CIRI development.
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